Navigation Links
Bioniche Provides a Corporate Update
Date:4/27/2009

BELLEVILLE, ON, April 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its corporate activities.

One of the near-term objectives of the Company, as reported in previous financial disclosures, is the conclusion of a partnering transaction related to its Mycobacterial Cell Wall-DNA Complex (MCC), formulated as Urocidin(TM), for the intravesical treatment of non-muscle-invasive bladder cancer. While the Company has received significant interest in Urodicin from a number of potential partners, it has not yet finalized a transaction and the timeline for doing so has exceeded management's expectations. Given such delays and the Company's near-term cash needs, the Board of Directors has decided to broaden its fundraising strategies to include possible asset dispositions.

In addition, the Company has amended the maturity date of its existing secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds) to June 30, 2009. Bioniche and Valens agreed to this extension to allow the Company time to identify new banking partner(s) after Valens decided to retrench its activities due to credit market conditions, as well as to allow the Company to execute its near-term corporate objectives. This amendment will replace the previously agreed "on demand" status, with an additional fee applicable at maturity of the facility.

The Company is also expanding internal cost cutting measures introduced during the past two fiscal quarters to help address its near-term liquidity requirements.

The Company expects to release its Fiscal 2009 third quarter financial results on May 6, 2009.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal has been to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
2. Bioniche Revolving Credit Facility Maturity Date Amended
3. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
4. Bioniche Warrants Expiration Date to be Extended
5. Bioniche Reports Fiscal 2009 Second Quarter
6. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
7. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
8. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
9. Bioniche Reports Fiscal 2009 First Quarter
10. Bioniche Allows Conversion of Portion of Revolving Credit Facility
11. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... ... , ... Springfield, Vermont-based law firm of Brady/Callahan has released a new Personal ... An Experienced Personal Injury Attorney, " the article offers insight for people who have ... says. if someone is injured due to another person's negligence, they may ...
(Date:5/19/2017)... FL (PRWEB) , ... May 19, 2017 , ... ... asset protection services and retirement planning assistance to families and business owners in ... Sclerosis Society to advocate for MS sufferers and their families. , Multiple sclerosis ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... announced a sponsorship and speaking session at the 7th Annual ET6 Exchange ... hosted enterprise mobility and digital transformation conference whose expressed purpose is to connect ...
(Date:5/19/2017)... ... 2017 , ... ML Billing, 2016 Billing Company of the Year , ... large group practices, is pleased to announce their 30th anniversary. Not only has ML ... in all aspects of full-service medical billing. This has allowed ML Billing to excel ...
(Date:5/19/2017)... ... May 18, 2017 , ... ... who served eight American presidents of both political parties, will become the 9th ... General Colin L. Powell, USA (Retired) as Chairman in May, 2018. , Secretary ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)... PORTLAND, Ore. , May 9, 2017 /PRNewswire/ ... company that provides technology solutions to improve the ... reported financial results for the first quarter ended ... that our products enable our customers to identify ... them to intervene before events like heart attacks ...
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
Breaking Medicine Technology: